4.5 Article

A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response

期刊

VACCINE
卷 26, 期 32, 页码 4006-4014

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.05.028

关键词

dendritic cells; memory T cells; adjuvant

资金

  1. Bill & Melinda Gates Foundation
  2. European Commission [LSHP-CT-2005-012161]

向作者/读者索取更多资源

A strategy to improve the immunogenicity of candidate vaccines is to trigger the innate immune system. Triggering of CD40 at the surface of dendritic cells (DC) is essential in the induction of an efficient immune response. Although CD40 agonist antibodies have been shown to be potent inducers of immune responses in experimental models, serious safety concerns have been raised for their use in humans. In addition, the production of soluble functional CD40 ligand has been challenging and the soluble form existing so far is not developed anymore. Here, we have evaluated the potency of a new soluble form of hexameric CD40 ligand (sCD40L) to serve as an adjuvant for anti-viral T cell responses. sCD40L was able to activate human DC and to enhance virus-specific memory T cell responses. These results demonstrate that this soluble form of CD40 ligand may serve as an adjuvant for T cell response and thus provide the rationale for its potential use in T cell based vaccine strategies. (C) 2008 Published by Elsevier Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据